SLN & Lymphadenectomy in early stage cervical cancer Lcuru F, - - PowerPoint PPT Presentation

▶
sln lymphadenectomy in early stage cervical cancer
SMART_READER_LITE
LIVE PREVIEW

SLN & Lymphadenectomy in early stage cervical cancer Lcuru F, - - PowerPoint PPT Presentation

Mar 10, 2023 172 likes •361 views

Gynecologic Cancer InterGroup Cervix Cancer Research Network SLN & Lymphadenectomy in early stage cervical cancer Lcuru F, Mathevet P, Balaya V, Ng C, Delomnie M, Bonsang Kitzis H, Bats AS, Nguyen HT, Koual M, Nos C. Gynecologic and

slide-1
SLIDE 1

Gynecologic Cancer InterGroup Cervix Cancer Research Network

SLN & Lymphadenectomy in early stage cervical cancer

Lécuru F, Mathevet P, Balaya V, Ngô C, Deloménie M, Bonsang Kitzis H, Bats AS, Nguyen HT, Koual M, Nos C. Gynecologic and Breast Oncologic surgical Dept Georges Pompidou European Hospital, Paris, France Faculté de Médecine, Paris Descartes University, Paris, France Lausanne University Hospital. www.cancerologiegynecologique.eu

Cervix Cancer Education Symposium, January 2019, South Africa

slide-2
SLIDE 2

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

slide-3
SLIDE 3

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

slide-4
SLIDE 4

Gynecologic Cancer InterGroup Cervix Cancer Research Network

ECC: Risk factors of recurrence

  • Lymph node metastases
  • Large cervical tumor (>4cm)
  • Parametrial extension
  • Non squamous histology
  • Deep (>75%) stromal invasion
  • LVSI

Cervix Cancer Education Symposium, January 2019, South Africa

Fuller A & al 1989 Schorge J & al 1997 Landoni F & al 1997 Lennox G & al 2017

slide-5
SLIDE 5

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Prognosis = Nodes

Prognosis is different between N0 et N1 patients (macrometastases)* Better prognosis in “occult” metastases vs macroscopic Poorer prognosis with increasing number of nodes, if ≥ 2 (10% 5-year DFS / node) Prognosis linked to location of nodes (the highest the worst) Prognosis of N+ depends of parametrial invasion

Cervix Cancer Education Symposium, January 2019, South Africa

van Bommel P & al 1987 Delgado G & al 1990 Inoue T & al 1990 Suprasert P & al 2013 Tinga D & al 1990 Tsai C & al 1999

slide-6
SLIDE 6

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Feature of nodal involvement

5 to 20% patients from Ia1 to IIa have metastatic lymph nodes. Only ONE node is invaded in 35-54.8% of patients pN1 Small size of the metastasis ➢ Median size of metastasis is 1.5 mm ➢ 22 to 38% measure less than 2mm ➢100% of metastases measure less than 8 mm

Cervix Cancer Education Symposium, January 2019, South Africa

Inoue 1990 Cancer Benedetti Panici 1996 GynOncol Lee K 2006 JOGR Horn 2008 GynOncol Gortzak Uzan 2010 GynOncol Achouri 2013 EJSO

slide-7
SLIDE 7

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Lymphadenectomy or SLN ?

Cervix Cancer Education Symposium, January 2019, South Africa

slide-8
SLIDE 8

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Lymphadenectomy

  • ext iliac, obt, hypoG,

common iliac, PA?

  • >10 nodes to be

informative

  • lymphedema if >10 nodes
  • limited pathologic analysis

SLN

  • targeted biopsy
  • enhanced pathology
  • unexpected locations
  • false negative !

Cervix Cancer Education Symposium, January 2019, South Africa

slide-9
SLIDE 9

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

Sakuragi N & al 1999 Abu Rustum N & al 2007

slide-10
SLIDE 10

Gynecologic Cancer InterGroup Cervix Cancer Research Network

SLN

Cervix Cancer Education Symposium, January 2019, South Africa

  • Location of the SN:

Senticol1 Senticol2 – External iliac/ obturator: 83,5% 85,8% – Para-aortic + presacral: 5,1% 2,6% – Common iliac: 8,5% 9,5% – Parametrium : 2,7% 1,1%

Lécuru F & al 2011 Mathevet P & al 2016

slide-11
SLIDE 11

Gynecologic Cancer InterGroup Cervix Cancer Research Network

To Lower the FN rate

Cervix Cancer Education Symposium, January 2019, South Africa

  • Stage Ia1 – IIa1
  • No suspicious lymph node on pre-operative imaging and

per-operative assessment

  • Tumour size <40mm
  • Bilateral detection
  • MSKCC algorithm

FN rate: 1/1257 (0.08%)

Tax C & al 2015

slide-12
SLIDE 12

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

Blue Dye Isotope ICG Learning curve 10 - 15 10 - 15 <10* DR, bilat DR + ++ +++ Cost 25€ 373€ 45€ Reglementation No Complex No (not allowed) Risk ++ (<2%) + (<2/1000) Easy handling Yes Moderate Yes * Detection ergonomy Yes § Moderate $ Yes £ Delay inj-detection Short (15 min) Long Short (<10min) Obese patients + +++ +++ Control Ex vivo Imaging, ex vivo Ex vivo Leakage Yes No No Parametrium Risk FN Risk FN Good

  • * Possibility of re-injection
  • $ coordination with nuclear medicine
  • § Blue on the cervix and surrounding tissue
  • £ non visible without IR light
slide-13
SLIDE 13

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

slide-14
SLIDE 14

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

Ib1 – IIb CC RH + PLN pN0 and >5 years FU Ultrastaging (/3µ + IHC)

  • 83 patients included

– 15 with recurrences (18%)

  • 13 pelvis
  • 1 lung & liver
  • 1 lung

– 68 without recurrence

  • 6 patients (7%) with

micromet

  • Xvariate for recurrence

– Micrometastases (OR 11.73) – T diameter (≤2cm vs >2cm) (OR 4.42)

Colturato L & al 2016

slide-15
SLIDE 15

Gynecologic Cancer InterGroup Cervix Cancer Research Network

ESMO - ESTRO - ESP guidelines

  • stage Ia1 with LVSI

LN can be considered, SLN is adequate

  • stage Ia2,

LVSI- LN can be considered, SLN is acceptable LVSI+ LN can be considered, SLN is adequate

  • stage Ib1 - Ia2

pre-operative nodal staging by imaging (MRI > US) if negative, the LN assessment should be performed as the first

  • step. SLN is strongly recommended.

intra-operative assessment of LN is recommended (SLN, LN, suspicious LN) negative: PLND positive: +/- PALND

Cervix Cancer Education Symposium, January 2019, South Africa

slide-16
SLIDE 16

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

Still indications for lymphadenectomy ?

  • Patients with Ib2 or IIb stages ?
  • After neo-adjuvant chemotherapy ?
  • Patients with pos SLN ?
slide-17
SLIDE 17

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

Thank you

www.cancerologiegynecologique.eu fabrice.lecuru@aphp.fr patrice.mathevet@chuv.ch